KPV vs BPC-157: Research Comparison | Peptide Intel Hub

KPV (Lysine-Proline-Valine) is the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH). Its proposed mechanism in research models centres on anti-inflammatory signalling related to the melanocortin axis — specifically downregulation of pro-inflammatory cytokine response and NF-κB-axis modulation.

BPC-157 (Body Protective Compound 157) is a synthetic 15-amino-acid pentadecapeptide derived from a partial sequence of human gastric juice protein. Its proposed mechanism in research models is multi-axis — angiogenic-axis modulation, growth-factor-axis interaction, and broader tissue-repair signalling — with a wider pharmacological footprint than KPV.

KPV's proposed receptor profile is melanocortin-related, with downstream effects on inflammatory signalling pathways. The tripeptide structure gives it a narrower pharmacological footprint than longer anti-inflammatory peptides.

BPC-157 does not act through a single well-characterised receptor. Published research suggests interactions with multiple growth-factor and angiogenic pathways, which is the proposed basis for its broader tissue-repair research profile.

KPV is a short tripeptide with a short native half-life. Research cadences are typically daily or sub-daily; oral, topical and subcutaneous research-administration routes have been reported in the literature.

BPC-157 is a 15-residue peptide with notable stability in gastric conditions — oral, subcutaneous and intraperitoneal research-administration routes are documented. Research cadences vary depending on the route.

KPV is widely used in research models of inflammatory bowel conditions, skin and mucosal inflammation, and as a comparator anti-inflammatory peptide in melanocortin-axis studies. The tripeptide structure simplifies analytical work compared with longer peptides.

BPC-157 is widely used in research models of tendon, ligament, muscle and gastrointestinal tissue repair, and in angiogenesis research. The broader proposed mechanism gives it a wider research-application footprint than KPV.

Both KPV and BPC-157 ship from Regena Peptides only after independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds are published on the Regena Peptides lab reports page so a research-peptide buyer can audit the analytical detail before purchase. The /trust/how-to-read-a-coa reference walks through every field on a modern Regena Peptides COA.

Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a two-month (60-day) in-use stability window under refrigeration for both compounds.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both KPV and BPC-157 benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose KPV when the protocol targets melanocortin-related anti-inflammatory signalling specifically — typically mucosal-inflammation, skin-inflammation or IBD research models. Researchers choose BPC-157 when the protocol targets broader tissue-repair, angiogenic-axis or musculoskeletal-repair research applications, or when a multi-axis pharmacological profile is part of the experimental design.

For multi-compound comparator studies, the Regena Peptides consultations team will reserve matched-batch inventory of both KPV and BPC-157 against a project timeline so the experimental panel is sourced under a single analytical specification window.

Both KPV and BPC-157 are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on the Regena Peptides site exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.